Medicus Pharma sells 4.47M shares for $3.85M under Yorkville SEPA through Mar 6, 2026

Medicus Pharma Ltd.

Total of 4,471,038 common shares sold under SEPA from Dec 2025 to Mar 2026 for aggregate $3,846,910.
Largest single draw: 1,425,000 shares on Mar 6, 2026 for approx $640,110.
Proceeds used partly to prepay outstanding debenture with Yorkville (previously disclosed in Sep 2025 8-K).
Yorkville may resell shares under an effective registration statement; additional draws possible subject to SEPA conditions.
Sales rely on Section 4(a)(2) exemption; Yorkville represented itself as an accredited investor.

item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Medicus Pharma Ltd. issued 4,471,038 of common stock to YA II PN, Ltd. for $3,846,910.

Security: common stock
Shares: 4,471,038
Purchaser: YA II PN, Ltd.
Consideration: $3,846,910

Exact text from the filing

the Company completed sales of its common shares (the "Common Shares") to Yorkville (collectively, the "SEPA Advances") as disclosed in the table below: Date of Sale Number of Common Shares Approximate Aggregate Consideration December 19, 2025 66,667 $113,647 December 19, 2025 5,432 $9,221 December 29, 2025 41,250 $66,149 December 29, 2025 20,909 $32,451 January 9, 2026 100,000 $150,640 January 15, 2026 33,333 $48,006 January 15, 2026 11,347 $15,960 January 29, 2026 7,100 $8,609 February 10, 2026 175,000 $186,603 February 18, 2026 250,000 $237,200 February 23, 2026 275,000 $302,088 March 5, 2026 700,000 $988,890 March 5, 2026 1,360,000 $1,047,336 March 6, 2026 1,425,000 $640,110 Total 4,471,038 $3,846,910

View on SEC.gov

1 equity issuances filed in the last 30 days. Browse all equity issuances →

Medicus Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001062993-26-001326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.